US2023279048A1PendingUtilityA1

Compositions containing hc-ha/ptx3 complexes and methods of use thereof

Assignee: BIOTISSUE HOLDINGS INCPriority: Jul 11, 2012Filed: Nov 1, 2022Published: Sep 7, 2023
Est. expiryJul 11, 2032(~6 yrs left)· nominal 20-yr term from priority
C07K 1/36A61K 38/191A61K 47/55A61K 47/69A61K 47/6957A61L 27/34A61L 27/54A61L 29/085A61L 29/16A61L 31/10A61L 31/16C07K 14/47C07K 14/525C07K 19/00A61K 38/00C07K 14/81A61P 1/02A61P 11/00A61P 17/00A61P 17/02A61P 19/00A61P 19/02A61P 19/04A61P 19/08A61P 19/10A61P 25/00A61P 27/02A61P 29/00A61P 31/04A61P 35/00A61P 37/02A61P 37/06A61P 37/08A61P 43/00A61P 9/00A61P 9/10A61P 3/10A61L 2300/236A61L 2300/252A61L 2300/41A61L 2300/412A61L 2300/426
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 - 148 . (canceled) 
     
     
         149 . A method of treating a cancer in an individual in need thereof, the method comprising administering a therapeutically effective amount of a Heavy Chain-Hyaluronan/Pentraxin 3 (HC-HA/PTX3) complex to the individual, thereby treating the cancer in the individual. 
     
     
         150 . The method of  claim 149 , wherein the Hyaluronan (HA) of the HC-HA/PTX3 complex comprises high molecular weight (HMW) HA. 
     
     
         151 . The method of  claim 149 , wherein the HC-HA/PTX3 complex comprises native HC-HA/PTX3 complex (nHC-HA/PTX3). 
     
     
         152 . The method of  claim 151 , wherein the nHC-HA/PTX3 complex is isolated from fetal tissue that is frozen or previously frozen. 
     
     
         153 . The method of  claim 152 , wherein the fetal tissue comprises amniotic membrane or umbilical cord extract. 
     
     
         154 . The method of  claim 152 , wherein the nHC-HA/PTX3 complex is isolated from amniotic membrane extract. 
     
     
         155 . The method of  claim 149 , wherein the HC-HA/PTX3 complex comprises reconstituted HC-HA/PTX3 (rcHC-HA/PTX3). 
     
     
         156 . The method of  claim 155 , wherein the rcHC-HA/PTX3 comprises hyaluronan (HA), heavy chain 1 (HC1), and pentraxin 3 (PTX3). 
     
     
         157 . The method of  claim 149 , wherein the individual is a human. 
     
     
         158 . The method of  claim 149 , wherein the treating comprises inhibiting the growth of cancer cells. 
     
     
         159 . The method of  claim 149 , wherein the treating comprises killing cancer cells. 
     
     
         160 . The method of  claim 149 , wherein the cancer comprises prostate cancer, colorectal cancer, liver cancer, kidney cancer, bladder cancer, brain cancer, ovarian cancer, lung cancer, melanoma, breast cancer, thyroid cancer, pancreatic cancer, stomach cancer, lung cancer, leukemia, lymphoma, sarcomas, gastric cancer, bone cancer, oral cancer, eye cancer, or carcinoma. 
     
     
         161 . The method of  claim 149 , wherein the cancer is pancreatic cancer. 
     
     
         162 . The method of  claim 149 , wherein the HC-HA/PTX3 complex is formulated for administration by injection. 
     
     
         163 . The method of  claim 149 , wherein the HC-HA/PTX3 complex is formulated as a powder. 
     
     
         164 . The method of  claim 149 , wherein the HC-HA/PTX3 complex is reconstituted with a pharmaceutically acceptable excipient prior to injection. 
     
     
         165 . The method of  claim 164 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of: a natural polymer, an adjuvant, a preservative, an agent for delaying absorption, a filler, a binder, an adsorbent, a buffer, and/or a combination thereof.

Join the waitlist — get patent alerts

Track US2023279048A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.